[go: up one dir, main page]

EA202091590A1 - Антитела против pd-l1 и варианты их применения - Google Patents

Антитела против pd-l1 и варианты их применения

Info

Publication number
EA202091590A1
EA202091590A1 EA202091590A EA202091590A EA202091590A1 EA 202091590 A1 EA202091590 A1 EA 202091590A1 EA 202091590 A EA202091590 A EA 202091590A EA 202091590 A EA202091590 A EA 202091590A EA 202091590 A1 EA202091590 A1 EA 202091590A1
Authority
EA
Eurasian Patent Office
Prior art keywords
seq
fragments
antibodies
antibodies against
application options
Prior art date
Application number
EA202091590A
Other languages
English (en)
Inventor
Лэй Фан
Юнцян ВАН
Чжэнъи Ван
Бинши Гуо
Цзинъу Цзан
Original Assignee
Ай-Маб Биофарма Юэс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ай-Маб Биофарма Юэс Лимитед filed Critical Ай-Маб Биофарма Юэс Лимитед
Publication of EA202091590A1 publication Critical patent/EA202091590A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Предложены антитела против PD-L1 или их фрагменты. Указанные антитела или их фрагменты специфически связываются с иммуноглобулиновым С-доменом белка PD-L1. В различных примерах указанные антитела или их фрагменты включают VH CDR1 из SEQ ID NO: 1, VH CDR2 из SEQ ID NO: 116, VH CDR3 из SEQ ID NO: 117, VL CDR1 из SEQ ID NO: 4, VL CDR2 из SEQ ID NO: 5 и VL CDR3 из SEQ ID NO: 6 или варианты каждого из перечисленных. Также предложены способы применения указанных антител или их фрагментов для лечения и диагностики заболеваний, таких как рак и инфекционные заболевания.
EA202091590A 2018-03-29 2019-03-29 Антитела против pd-l1 и варианты их применения EA202091590A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018081079 2018-03-29
PCT/CN2019/080458 WO2019185029A1 (en) 2018-03-29 2019-03-29 Anti-pd-l1 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA202091590A1 true EA202091590A1 (ru) 2021-01-21

Family

ID=68060946

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091590A EA202091590A1 (ru) 2018-03-29 2019-03-29 Антитела против pd-l1 и варианты их применения

Country Status (18)

Country Link
US (2) US11220546B2 (ru)
EP (1) EP3589660A4 (ru)
JP (1) JP7124257B2 (ru)
KR (2) KR102475106B1 (ru)
CN (1) CN110891975B (ru)
AU (1) AU2019241339B2 (ru)
BR (1) BR112020019827A2 (ru)
CA (1) CA3086434C (ru)
CL (1) CL2020002223A1 (ru)
EA (1) EA202091590A1 (ru)
IL (1) IL275734B (ru)
MX (1) MX2020007842A (ru)
MY (1) MY188237A (ru)
PE (1) PE20210377A1 (ru)
PH (1) PH12020551173A1 (ru)
SG (1) SG11202006008WA (ru)
UA (1) UA125918C2 (ru)
WO (1) WO2019185029A1 (ru)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3325513A4 (en) * 2016-06-13 2018-12-19 I-Mab Anti-pd-l1 antibodies and uses thereof
WO2020020307A1 (en) * 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
AU2019326635B2 (en) * 2018-08-21 2024-05-23 Abl Bio Inc. Anti-PD-L1/anti-LAG3 bispecific antibodies and uses thereof
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
WO2021219092A1 (en) * 2020-04-30 2021-11-04 I-Mab Biopharma Co., Ltd. Pharmaceutical compositionscontaining anti-cd47 antibodies
IL299966A (en) * 2020-07-28 2023-03-01 Lepu Biopharma Co Ltd Bifunctional molecules targeting PD-L1 and TGF- in the cell
MX2023001962A (es) 2020-08-19 2023-04-26 Xencor Inc Composiciones anti-cd28.
CN114195900B (zh) * 2020-09-17 2024-02-23 普米斯生物技术(珠海)有限公司 一种抗4-1bb/pd-l1双特异性抗体及其用途
CN114316045B (zh) 2020-09-29 2024-07-12 英诺欧奇生物医药(苏州)有限公司 抗pd-l1抗体及其用途
CN113234162B (zh) * 2020-12-24 2022-05-13 四川大学华西医院 一种靶向cd133的嵌合抗原受体t细胞
EP4276466A4 (en) * 2021-01-08 2024-12-18 Beijing Hanmi Pharmaceutical Co., Ltd. ANTIBODY SPECIFICALLY BINDING WITH PD-L1 AND ANTIGEN-BINDING FRAGMENT OF ANTIBODY
CN115073599B (zh) * 2021-03-16 2023-04-28 北京天广实生物技术股份有限公司 结合pd-l1的抗体及其用途
KR20240166575A (ko) * 2022-04-02 2024-11-26 하버 바이오메드 (상하이) 컴퍼니 리미티드 Pd-l1 및 cd40을 표적화하는 항원 결합 단백질, 이의 제조 방법 및 응용
WO2024104373A1 (en) * 2022-11-15 2024-05-23 I-Mab Biopharma Co., Ltd. Anti-pd-l1 nanobodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103059138B (zh) * 2005-05-09 2015-10-28 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
WO2011043194A1 (en) 2009-10-09 2011-04-14 Semiconductor Energy Laboratory Co., Ltd. Semiconductor device and method for manufacturing the same
US20170015758A1 (en) * 2014-01-21 2017-01-19 Medimmune, Llc Compositions And Methods For Modulating And Redirecting Immune Responses
KR102130600B1 (ko) 2014-07-03 2020-07-08 베이진 엘티디 Pd-l1 항체와 이를 이용한 치료 및 진단
FI4141032T3 (fi) * 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
CN105777906B (zh) * 2014-12-19 2019-04-23 苏州丁孚靶点生物技术有限公司 抗pd-l1全人抗体及其应用
CN106939047B (zh) * 2016-01-04 2021-08-31 江苏怀瑜药业有限公司 一种pd-l1抗体及其制备方法
EP3325513A4 (en) * 2016-06-13 2018-12-19 I-Mab Anti-pd-l1 antibodies and uses thereof
CN107488229B (zh) * 2016-06-13 2020-11-17 天境生物科技(上海)有限公司 Pd-l1抗体及其用途
CN108777906B (zh) 2018-06-25 2020-06-16 珠海惠尔益电子科技有限公司 一种双灯组变焦电路及头灯
WO2020020307A1 (en) * 2018-07-25 2020-01-30 I-Mab Biopharma Co., Ltd. Anti-cd73 anti-pd-l1 bispecific antibodies
CN113286825B (zh) * 2018-11-30 2024-06-18 爱必乐生物公司 抗pd-l1/抗4-1bb双特异性抗体及其用途

Also Published As

Publication number Publication date
WO2019185029A1 (en) 2019-10-03
US20200157222A1 (en) 2020-05-21
AU2019241339B2 (en) 2021-08-12
CN110891975B (zh) 2023-11-10
CL2020002223A1 (es) 2021-01-29
KR102475106B1 (ko) 2022-12-08
IL275734B (en) 2022-06-01
EP3589660A4 (en) 2021-04-07
KR102177931B1 (ko) 2020-11-13
IL275734A (en) 2020-08-31
BR112020019827A2 (pt) 2021-01-05
CA3086434A1 (en) 2019-10-03
UA125918C2 (uk) 2022-07-06
US20220119531A1 (en) 2022-04-21
AU2019241339A1 (en) 2019-11-14
MY188237A (en) 2021-11-24
KR20190128716A (ko) 2019-11-18
KR20200130747A (ko) 2020-11-19
CN110891975A (zh) 2020-03-17
NZ758371A (en) 2024-10-25
JP2020518233A (ja) 2020-06-25
EP3589660A1 (en) 2020-01-08
CA3086434C (en) 2024-01-09
PH12020551173A1 (en) 2021-05-31
US11220546B2 (en) 2022-01-11
PE20210377A1 (es) 2021-03-02
MX2020007842A (es) 2020-09-25
SG11202006008WA (en) 2020-07-29
JP7124257B2 (ja) 2022-08-24

Similar Documents

Publication Publication Date Title
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения
PH12018502623B1 (en) Anti-pd-l1 antibodies and uses thereof
EA201991099A1 (ru) Антитела против cd73 и их применение
AR111630A1 (es) ANTICUERPOS ANTI-SIRPa
FI3389699T3 (fi) Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja
NZ628528A (en) Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
JP2019535763A5 (ru)
IL299221A (en) CD3 binding antibodies
AR109715A1 (es) Anticuerpos anti-cd27
JOP20190248A1 (ar) بروتينات ربط مولد ضد trem2 واستخداماته
EP4435009A3 (en) Claudin6 antibodies and methods of treating cancer
JP2018527919A5 (ru)
HRP20201022T1 (hr) Potpuno ljudsko antitijelo protiv ljudskog cd137 i njegova uporaba
RU2016100892A (ru) Антитела против tweakr и их применение
NZ625403A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
EA201790342A1 (ru) Антитела к trem2 и способы их применения
MA40913A (fr) Conjugués anticorps-médicament
UA115781C2 (uk) Cx3cr1-зв'язуючий поліпептид
CN112513094A (zh) 结合人her2的抗体、其制备方法和用途
JP2016502515A5 (ru)
JP2016530223A5 (ru)
EP4403226A3 (en) Anti-psma antibodies, uses thereof and conjugates thereof
RU2018121413A (ru) Антитело ANTI-PCSK9 и его применение
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
EA201790816A1 (ru) Антитела, которые связываются с ccr6, и варианты применения указанных антител